169
Participants
Start Date
December 31, 2015
Primary Completion Date
June 30, 2020
Study Completion Date
November 30, 2020
SGX301 (synthetic hypericin)
0.25% SGX301 in USP Hydrophilic Ointment applied twice per week, covered by opaque bandage for 12-24 hours, then treated with an initial dose of 5 J/cm\^2 fluorescent light.
Placebo
USP Hydrophilic Ointment applied twice per week, covered by opaque bandage for 12-24 hours, then treated with an initial dose of 5 J/cm\^2 fluorescent light.
Columbia University Medical Center, New York
Stony Brook Medicine, Stony Brook
Rochester Skin Lymphoma Medical Group, Fairport
University of Pittsburgh Medical Center, Pittsburgh
Hospital of the University of Pennsylvania, Philadelphia
Jefferson Dermatology, Philadelphia
University of Maryland, Baltimore
INOVA Schar Cancer Institute, Fairfax
Virginia Clinical Research, Norfolk
PMG Research of Wilmington, Wilmington
Medical University of South Carolina, Charleston
Leon Medical Research, Miami
Medical Professional Clinical Research, Miami
University of South Florida, Tampa
Olympian Clinical Research, Clearwater
University of Alabama Birmingham, Birmingham
Vanderbilt University, Nashville
University Hospitals Cleveland Medical Center, Cleveland
Dawes Fretzin Dermatology Group, Indianapolis
University of Minnesota, Minneapolis
Northwestern University, Chicago
Rush University, Chicago
Washington University, St Louis
Tulane University, New Orleans
University of Arkansas, Little Rock
MD Anderson, Houston
Austin Institute for Clinical Research, Pflugerville
University of Arizona, Phoenix
Mayo Clinic, Scottsdale
Therapeutics Clinical Research, San Diego
Stanford University, Palo Alto
Seattle Care Cancer Center, Seattle
Dartmouth-Hitchcock Medical Center, Lebanon
Lead Sponsor
Soligenix
INDUSTRY